Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Overview of attention for article published in Experimental Hematology & Oncology, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#22 of 347)
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 1 news outlet

twitter: 7 X users

Citations

dimensions_citation: 66 Dimensions

Readers on

mendeley: 77 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

BioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC Market

Seeking Alpha, 22 May 2023

Summary BioNTech SE has initiation of a phase 3 study using BNT316 as a monotherapy for PD-1/PD-L1 refractory non-small cell…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.